Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
Status:
Recruiting
Trial end date:
2022-09-24
Target enrollment:
Participant gender:
Summary
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high
risk of COVID-19 associated complications and mortality. Retrospective studies so far have
shown that a majority of SOT recipients did not develop appreciable anti-spike antibody
response after a first, second, or even third dose of mRNA vaccine. Treatment with
antimetabolites was associated with poor vaccine response. The goal of this study is 1)
examine whether transient immunosuppression reduction improves the immune response to a third
dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety
of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.